

November 01, 2018

**To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001**

**To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Glenmark launches globally-renowned hair growth formula Nourkrin® in Russia

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

**Harish Kuber
Company Secretary & Compliance Officer**

Encl: as above

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Press Release

For immediate release

Glenmark launches globally-renowned hair growth formula Nourkrin® in Russia

- Glenmark has launched Nourkrin® in Russia under an exclusive licensing agreement with Denmark-headquartered Pharma Medico

Mumbai, India, November 01, 2018: Glenmark Pharmaceuticals Ltd., a research-led globally integrated pharmaceutical company, today announced the launch of Nourkrin® in Russia. Nourkrin® is a globally-renowned, clinically-proven proteoglycan replacement formula, for addressing one of the key underlying causes of hair loss in males and females.

Nourkrin® Woman and Nourkrin® Man will be exclusively marketed in Russia by Glenmark Impex LLC, the Russian subsidiary of Glenmark Pharmaceuticals Ltd., under a licensing agreement with Denmark-headquartered firm Pharma Medico ApS.

Glenmark had already launched Nourkrin® Woman in India in early 2018.

Nourkrin® contains Marilex®, a unique and proprietary scientific formula, rich in specific proteoglycans essential for hair follicle growth. Nourkrin® is a proven formula based on more than 56 scientific studies and is recognized by leading regulatory agencies globally.

“We are very happy to launch Nourkrin for both women and men in Russia. It is a much awaited product, as the problem of hair loss affects quite a significant proportion of the population. Glenmark has a strong portfolio of dermatology products in Russia offering patients relief from different types of skin disorders for several decades and Nourkrin will be a great addition to this portfolio,” **Csaba Kantor, Senior Vice President & Head - Asia, Russia & CIS, Glenmark Pharmaceuticals, said.**

According to a survey conducted by market research firm GfK in 2017, 18.7 million women and 14.1 million men in Russia experienced hair loss over the preceding 12 months.

Nourkrin® Woman and Nourkrin® Man, available as tablets, are an easy-to-use therapy compared to clinical procedures and hair sprays and creams. The product will be available through retail pharmacy chains as well as online pharmacies.

About Glenmark Dermatology in Russia:

Glenmark as an organization has always had a formidable presence in the field of dermatology in Russia. As per IQVIA MAT August 2018 data, Glenmark ranked among the Top 10 dermatological pharma companies in this market. Brands such as Candid, Sertamycol, Oflomil nail lacquer (first amorolfine generic on the market), Keto Plus, and Klenzit are widely known by the patients and healthcare professionals in Russia. The latter two products - Keto Plus and Klenzit C being unique combinations available on the Russian market. All products are among the leaders in their respective categories.

About Glenmark Pharmaceuticals Ltd:

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For more information, please contact:

Isha Trivedi

Glenmark, Mumbai, India

Tel: +91 22 4018 9801

Email: corpcomm@glenmarkpharma.com